This site became the new ClinicalTrials.gov on June 19th. Learn more.
Show more
ClinicalTrials.gov Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu
Give us feedback

Study Evaluating ACC-001 In Subjects With Mild To Moderate Alzheimer's Disease

This study has been completed.
Sponsor:
Collaborator:
JANSSEN Alzheimer Immunotherapy Research & Development, LLC
Information provided by (Responsible Party):
Pfizer
ClinicalTrials.gov Identifier:
NCT00498602
First received: July 9, 2007
Last updated: November 30, 2015
Last verified: November 2015
History of Changes
Results First Received: April 23, 2014  
Study Type: Interventional
Study Design: Allocation: Randomized;   Intervention Model: Parallel Assignment;   Masking: Double Blind (Participant, Care Provider, Investigator, Outcomes Assessor);   Primary Purpose: Treatment
Condition: Alzheimer Disease
Interventions: Biological: ACC-001 + QS-21
Biological: QS-21
Other: Diluent: Phosphate Buffered Saline
Biological: ACC-001

  Participant Flow
  Hide Participant Flow

Recruitment Details
Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
Planned duration was approximately 110 weeks (including 6 week screening period, 52 weeks of dosing, and 52 weeks of follow-up). Participants who completed the NCT00498602 study through Week 78 had the option to exit after this time point, for continued treatment and follow-up under extension protocol extension protocol NCT00960531.

Pre-Assignment Details
Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
The Basic Results disclose pooled data from studies NCT00479557 and NCT00498602.

Reporting Groups
  Description
ACC 3 μg+QS-21 Participants received 3 μg of ACC-001 and 50 μg of QS-21. Test article was given by intramuscular injection into the deltoid muscle at 0, 1, 3, 6, and 12 months.
ACC 10 μg+QS-21 Participants received 10 μg of ACC-001 and 50 μg of QS-21. Test article was given by intramuscular injection into the deltoid muscle at 0, 1, 3, 6, and 12 months.
ACC 30 μg+QS-21 Participants received 30 μg of ACC-001 and 50 μg of QS-21. Test article was given by intramuscular injection into the deltoid muscle at 0, 1, 3, 6, and 12 months.
ACC 10 μg Participants received 10 μg of ACC-001. Test article was given by intramuscular injection into the deltoid muscle at 0, 1, 3, 6, and 12 months.
ACC 30 μg Participants received 30 μg of ACC-001. Test article was given by intramuscular injection into the deltoid muscle at 0, 1, 3, 6, and 12 months.
QS-21 Alone Participants received 50 μg of QS-21. Test article was given by intramuscular injection into the deltoid muscle at 0, 1, 3, 6, and 12 months.
Phosphate Buffered Saline Participants received Phosphate buffered Saline (PBS). Test article was given by intramuscular injection into the deltoid muscle at 0, 1, 3, 6, and 12 months.

Participant Flow:   Overall Study
    ACC 3 μg+QS-21   ACC 10 μg+QS-21   ACC 30 μg+QS-21   ACC 10 μg   ACC 30 μg   QS-21 Alone   Phosphate Buffered Saline
STARTED   36   61   40   35   12   44   17 
Treated   36   60 [1]   40   35   12   44   17 
COMPLETED   26   51   32   30   8   31   15 
NOT COMPLETED   10   10   8   5   4   13   2 
Death                0                0                0                0                0                1                0 
Lack of Efficacy                1                0                0                0                0                0                0 
Lost to Follow-up                0                2                0                2                0                0                0 
Adverse Event (AE) related to Study Drug                1                0                3                2                0                1                0 
AE not related to Study Drug                1                3                0                0                2                2                1 
Caregiver Request                2                2                2                0                1                2                0 
Investigator Request                0                0                1                0                0                0                0 
Subject Request                3                0                1                1                1                4                1 
Not specified                2                3                1                0                0                3                0 
[1] One participant discontinued due to an AE, with an outcome of death.



  Baseline Characteristics
  Hide Baseline Characteristics

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
245 participants were randomized in both studies (86 participants in NCT00479557 and 159 participants in NCT00498602) are included in the analysis below. One participant of the randomized participants did not receive treatment.

Reporting Groups
  Description
ACC 3 μg+QS-21 Participants received 3 μg of ACC-001 and 50 μg of QS-21. Test article was given by intramuscular injection into the deltoid muscle at 0, 1, 3, 6, and 12 months.
ACC 10 μg+QS-21 Participants received 10 μg of ACC-001 and 50 μg of QS-21. Test article was given by intramuscular injection into the deltoid muscle at 0, 1, 3, 6, and 12 months.
ACC 30 μg+QS-21 Participants received 30 μg of ACC-001 and 50 μg of QS-21. Test article was given by intramuscular injection into the deltoid muscle at 0, 1, 3, 6, and 12 months.
ACC 10 μg Participants received 10 μg of ACC-001. Test article was given by intramuscular injection into the deltoid muscle at 0, 1, 3, 6, and 12 months.
ACC 30 μg Participants received 30 μg of ACC-001. Test article was given by intramuscular injection into the deltoid muscle at 0, 1, 3, 6, and 12 months.
QS-21 Alone Participants received 50 μg of QS-21. Test article was given by intramuscular injection into the deltoid muscle at 0, 1, 3, 6, and 12 months.
Phosphate Buffered Saline Participants received PBS. Test article was given by intramuscular injection into the deltoid muscle at 0, 1, 3, 6, and 12 months.
Total Total of all reporting groups

Baseline Measures
   ACC 3 μg+QS-21   ACC 10 μg+QS-21   ACC 30 μg+QS-21   ACC 10 μg   ACC 30 μg   QS-21 Alone   Phosphate Buffered Saline   Total 
Overall Participants Analyzed 
[Units: Participants]
 		 36   61   40   35   12   44   17   245 
Age 
[Units: Years]
Mean (Standard Deviation) 		 65.7  (7.75)   69.3  (9.57)   69.0  (9.27)   71.9  (8.96)   70.9  (9.59)   68.8  (8.07)   69.4  (7.82)   69.1  (8.87) 
Gender 
[Units: Participants]
 		               
Female   16   29   22   19   8   31   14   139 
Male   20   32   18   16   4   13   3   106 
Race/Ethnicity, Customized 
[Units: Number of participants]
 		               
Asian   0   0   0   0   1   0   0   1 
Black or African American   1   0   1   0   0   1   0   3 
Other   2   1   1   1   0   0   0   5 
White   33   60   38   34   11   43   17   236 
Mini-Mental State Examination (MMSE) Score [1] 
[Units: Score]
Mean (Standard Deviation) 		 21.4  (2.96)   21.4  (3.38)   21.0  (2.92)   21.6  (3.16)   21.8  (3.60)   21.7  (3.11)   21.2  (3.17)   21.4  (3.13) 
[1] The MMSE was used to systematically and thoroughly assess mental status of participants. It is an 11-question measure that tests five areas of cognitive function: orientation, registration, attention and calculation, recall, and language. The total score ranges from 0 to 30. A score of 23 or lower is indicative of cognitive impairment.
MMSE Stratum [1] 
[Units: Number of participants]
 		               
High (21 - 26)   26   40   24   23   8   29   11   161 
Low (16 - 20)   10   21   16   12   4   15   6   84 
[1] The MMSE was used to systematically and thoroughly assess mental status of participants. It is an 11-question measure that tests five areas of cognitive function: orientation, registration, attention and calculation, recall, and language. The total score ranges from 0 to 30. A score of 23 or lower is indicative of cognitive impairment.


  Outcome Measures
  Hide All Outcome Measures

1.  Primary:   Percentage of Participants With Treatment-emergent AEs or Serious Adverse Events (SAEs)   [ Time Frame: approximately 110 weeks, including a 6-week screening period, 52 weeks of dosing and 54 weeks for follow-up after the last dose ]

Measure Type Primary
Measure Title Percentage of Participants With Treatment-emergent AEs or Serious Adverse Events (SAEs)
Measure Description An AE was any untoward, undesired, or unplanned clinical event in the form of signs, symptoms, disease, or laboratory or physiologic observations occurring in a person given study drug or in a sponsor’s clinical study. The event did not need to be causally related to the study drug or the clinical studies. A treatment emergent AE was defined as an event that emerged during the treatment period that was absent before treatment, or worsened during the treatment period relative to the pretreatment state. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly.
Time Frame approximately 110 weeks, including a 6-week screening period, 52 weeks of dosing and 54 weeks for follow-up after the last dose  

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
The safety population included all randomized participants with documented use of at least one dose of study drug.

Reporting Groups
  Description
ACC 3 μg+QS-21 Participants received 3 μg of ACC-001 and 50 μg of QS-21. Test article was given by intramuscular injection into the deltoid muscle at 0, 1, 3, 6, and 12 months.
ACC 10 μg+QS-21 Participants received 10 μg of ACC-001 and 50 μg of QS-21. Test article was given by intramuscular injection into the deltoid muscle at 0, 1, 3, 6, and 12 months.
ACC 30 μg+QS-21 Participants received 30 μg of ACC-001 and 50 μg of QS-21. Test article was given by intramuscular injection into the deltoid muscle at 0, 1, 3, 6, and 12 months.
ACC 10 μg Participants received 10 μg of ACC-001. Test article was given by intramuscular injection into the deltoid muscle at 0, 1, 3, 6, and 12 months.
ACC 30 μg Participants received 30 μg of ACC-001. Test article was given by intramuscular injection into the deltoid muscle at 0, 1, 3, 6, and 12 months.
QS-21 Alone Participants received 50 μg of QS-21. Test article was given by intramuscular injection into the deltoid muscle at 0, 1, 3, 6, and 12 months.
Phosphate Buffered Saline Participants received Phosphate buffered Saline (PBS). Test article was given by intramuscular injection into the deltoid muscle at 0, 1, 3, 6, and 12 months.

Measured Values
   ACC 3 μg+QS-21   ACC 10 μg+QS-21   ACC 30 μg+QS-21   ACC 10 μg   ACC 30 μg   QS-21 Alone   Phosphate Buffered Saline 
Participants Analyzed 
[Units: Participants]
 		 36   60   40   35   12   44   17 
Percentage of Participants With Treatment-emergent AEs or Serious Adverse Events (SAEs) 
[Units: Percentage of participants]
 		             
Percentage of participants with AEs   97.2   93.3   90.0   91.4   83.3   90.9   100 
Percentage of participants with SAEs   16.7   18.3   17.5   14.3   41.7   11.4   17.6 

No statistical analysis provided for Percentage of Participants With Treatment-emergent AEs or Serious Adverse Events (SAEs)



2.  Secondary:   Geometric Mean Titers (GMTs) of Anti-A-beta Immunoglobulin G (IgG) Total Using an Enzyme-linked Immunosorbent Assay (ELISA) at Weeks 2, 4, 6, 8, 10, 14, 16, 24, 28, 30, 40, 50, 54, 56, 66, 78, 91, and 104   [ Time Frame: Baseline, Week 2, 4, 6, 8, 10, 14, 16, 24, 28, 30, 40, 50, 54, 56, 66, 78, 91, and 104 ]

Measure Type Secondary
Measure Title Geometric Mean Titers (GMTs) of Anti-A-beta Immunoglobulin G (IgG) Total Using an Enzyme-linked Immunosorbent Assay (ELISA) at Weeks 2, 4, 6, 8, 10, 14, 16, 24, 28, 30, 40, 50, 54, 56, 66, 78, 91, and 104
Measure Description The lower limit of quantification (LLOQ) was 100 U/mL and when the assay result was below LLOQ (100 U/mL), 50 U/mL was imputed for IgG.
Time Frame Baseline, Week 2, 4, 6, 8, 10, 14, 16, 24, 28, 30, 40, 50, 54, 56, 66, 78, 91, and 104  

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
The immunogenicity population included all randomized participants with documented injection of at least one dose of study drug and at least one immunogenicity data point collected.

Reporting Groups
  Description
ACC 3 μg+QS-21 Participants received 3 μg of ACC-001 and 50 μg of QS-21. Test article was given by intramuscular injection into the deltoid muscle at 0, 1, 3, 6, and 12 months.
ACC 10 μg+QS-21 Participants received 10 μg of ACC-001 and 50 μg of QS-21. Test article was given by intramuscular injection into the deltoid muscle at 0, 1, 3, 6, and 12 months.
ACC 30 μg+QS-21 Participants received 30 μg of ACC-001 and 50 μg of QS-21. Test article was given by intramuscular injection into the deltoid muscle at 0, 1, 3, 6, and 12 months.
ACC 10 μg Participants received 10 μg of ACC-001. Test article was given by intramuscular injection into the deltoid muscle at 0, 1, 3, 6, and 12 months.
ACC 30 μg Participants received 30 μg of ACC-001. Test article was given by intramuscular injection into the deltoid muscle at 0, 1, 3, 6, and 12 months.
QS-21 Alone Participants received 50 μg of QS-21. Test article was given by intramuscular injection into the deltoid muscle at 0, 1, 3, 6, and 12 months.
Phosphate Buffered Saline Participants received Phosphate buffered Saline (PBS). Test article was given by intramuscular injection into the deltoid muscle at 0, 1, 3, 6, and 12 months.

Measured Values
   ACC 3 μg+QS-21   ACC 10 μg+QS-21   ACC 30 μg+QS-21   ACC 10 μg   ACC 30 μg   QS-21 Alone   Phosphate Buffered Saline 
Participants Analyzed 
[Units: Participants]
 		 36   60   40   35   12   44   17 
Geometric Mean Titers (GMTs) of Anti-A-beta Immunoglobulin G (IgG) Total Using an Enzyme-linked Immunosorbent Assay (ELISA) at Weeks 2, 4, 6, 8, 10, 14, 16, 24, 28, 30, 40, 50, 54, 56, 66, 78, 91, and 104 
[Units: U/mL]
Geometric Mean (95% Confidence Interval) 		             
Baseline (N: 36, 59, 40, 35, 12, 44, 17)   50.0 
 (50.0 to 50.0)  		 50.0 
 (50.0 to 50.0)  		 50.0 
 (50.0 to 50.0)  		 50.0 
 (50.0 to 50.0)  		 50.0 
 (50.0 to 50.0)  		 53.1 
 (47.1 to 59.8)  		 50.0 
 (50.0 to 50.0) 
Week 2 (N: 35, 60, 39, 35, 12, 43, 16)   56.6 
 (49.1 to 65.3)  		 69.0 
 (57.4 to 83.0)  		 86.5 
 (65.7 to 113.9)  		 51.7 
 (48.3 to 55.2)  		 50.0 
 (50.0 to 50.0)  		 52.5 
 (47.5 to 58.1)  		 50.0 
 (50.0 to 50.0) 
Week 4 (N: 35, 57, 38, 31, 12, 43, 16)   53.2 
 (48.5 to 58.4)  		 77.1 
 (61.9 to 96.0)  		 82.8 
 (63.0 to 108.8)  		 50.0 
 (50.0 to 50.0)  		 50.0 
 (50.0 to 50.0)  		 51.3 
 (48.7 to 53.9)  		 50.0 
 (50.0 to 50.0) 
Week 6 (N: 36, 58, 37, 33, 12, 41, 16)   634.8 
 (322.7 to 1248.5)  		 1089.4 
 (616.0 to 1837.2)  		 1343.5 
 (716.0 to 2521.1)  		 73.4 
 (50.6 to 106.4)  		 103.7 
 (38.2 to 281.4)  		 50.0 
 (50.0 to 50.0)  		 50.0 
 (50.0 to 50.0) 
Week 8 (N: 33, 57, 39, 33, 12, 41, 17)   497.4 
 (253.5 to 976.1)  		 885.2 
 (530.0 to 1478.7)  		 1098.2 
 (626.9 to 1924.0)  		 66.3 
 (48.2 to 91.1)  		 99.8 
 (38.8 to 256.6)  		 52.4 
 (47.6 to 57.7)  		 50.0 
 (50.0 to 50.0) 
Week 10 (N: 34, 59, 40, 33, 12, 43, 17)   292.3 
 (156.5 to 546.0)  		 762.8 
 (468.5 to 1242.2)  		 878.5 
 (531.3 to 1452.6)  		 77.0 
 (48.0 to 123.3)  		 94.9 
 (39.8 to 226.5)  		 53.0 
 (47.1 to 59.7)  		 50.0 
 (50.0 to 50.0) 
Week 14 (N: 33, 52, 39, 31, 11, 33, 14)   907.5 
 (474.6 to 1735.6)  		 2892.3 
 (1705.9 to 4903.8)  		 3136.8 
 (1877.6 to 5240.7)  		 89.6 
 (50.8 to 158.3)  		 199.4 
 (73.7 to 539.8)  		 50.0 
 (50.0 to 50.0)  		 50.0 
 (50.0 to 50.0) 
Week 16 (N: 33, 59, 38, 34, 12, 41, 16)   996.1 
 (487.1 to 2037.1)  		 3273.2 
 (2083.9 to 5141.4)  		 3324.7 
 (1959.9 to 5641.3)  		 91.7 
 (55.2 to 152.1)  		 133.9 
 (56.1 to 319.9)  		 52.6 
 (47.5 to 58.1)  		 50.0 
 (50.0 to 50.0) 
Week 24 (N: 34, 58, 37, 33, 10, 40, 16)   547.8 
 (278.8 to 1076.3)  		 1827.6 
 (1145.3 to 2916.1)  		 1231.3 
 (712.2 to 2128.6)  		 76.1 
 (52.1 to 111.1)  		 139.1 
 (52.1 to 371.3)  		 52.3 
 (47.4 to 57.4)  		 50.0 
 (50.0 to 50.0) 
Week 28 (N: 31, 51, 33, 29, 8, 36, 16)   2011.2 
 (986.9 to 4098.8)  		 4299.6 
 (2843.8 to 6500.8)  		 5407.7 
 (3676.0 to 7955.3)  		 108.9 
 (61.9 to 191.8)  		 334.1 
 (77.1 to 1448.3)  		 52.4 
 (47.6 to 57.6)  		 50.0 
 (50.0 to 50.0) 
Week 30 (N: 33, 56, 36, 32, 10, 38, 16)   2028.9 
 (1035.8 to 3973.8)  		 4316.8 
 (2900.2 to 6425.2)  		 4713.0 
 (3076.0 to 7221.2)  		 110.4 
 (64.1 to 190.0)  		 234.5 
 (65.3 to 842.5)  		 51.8 
 (48.2 to 55.7)  		 50.0 
 (50.0 to 50.0) 
Week 40 (N: 32, 54, 33, 33, 9, 37, 15)   1167.3 
 (609.1 to 2237.1)  		 2147.2 
 (1407.6 to 3275.3)  		 2292.9 
 (1436.6 to 3659.8)  		 97.2 
 (62.4 to 151.3)  		 211.0 
 (53.6 to 830.7)  		 52.1 
 (47.9 to 56.7)  		 50.0 
 (50.0 to 50.0) 
Week 50 (N: 29, 53, 33, 33, 9, 36, 16)   937.3 
 (482.0 to 1822.6)  		 1364.4 
 (911.9 to 2041.4)  		 1262.3 
 (828.5 to 1923.2)  		 80.7 
 (54.8 to 118.9)  		 168.4 
 (52.4 to 541.3)  		 52.8 
 (47.3 to 58.8)  		 50.0 
 (50.0 to 50.0) 
Week 54 (N: 27, 51, 30, 29, 9, 29, 14)   2031.6 
 (1024.2 to 4029.7)  		 5744.6 
 (3609.1 to 9143.7)  		 6677.3 
 (3678.7 to 12120.1)  		 160.6 
 (69.7 to 370.2)  		 491.6 
 (85.9 to 2812.2)  		 55.0 
 (45.2 to 66.9)  		 50.0 
 (50.0 to 50.0) 
Week 56 (N: 31, 52, 34, 32, 9, 34, 15)   2635.7 
 (1355.5 to 5125.2)  		 5906.1 
 (4058.8 to 8594.2)  		 7642.5 
 (5057.9 to 11547.9)  		 159.2 
 (74.2 to 341.8)  		 463.7 
 (81.1 to 2650.5)  		 53.4 
 (46.7 to 60.9)  		 50.0 
 (50.0 to 50.0) 
Week 66 (N: 31, 54, 34, 31, 9, 33, 15)   1372.0 
 (717.1 to 2625.1)  		 2867.4 
 (1835.9 to 4478.5)  		 2882.2 
 (1793.1 to 4632.8)  		 166.3 
 (78.8 to 350.9)  		 280.0 
 (56.3 to 1393.9)  		 63.5 
 (43.7 to 92.3)  		 50.0 
 (50.0 to 50.0) 
Week 78 (N: 31, 52, 32, 32, 8, 32, 14)   1108.4 
 (585.1 to 2099.4)  		 1867.5 
 (1197.4 to 2912.5)  		 1338.1 
 (827.3 to 2164.4)  		 142.7 
 (71.5 to 285.1)  		 256.1 
 (58.2 to 1128.2)  		 53.6 
 (46.5 to 61.6)  		 50.0 
 (50.0 to 50.0) 
Week 91 (N: 15, 9, 3, 8, 2, 6, 2)   1824.6 
 (1063.2 to 3131.2)  		 2497.0 
 (644.8 to 9670.1)  		 543.0 
 (33.6 to 8767.8)  		 76.8 
 (27.8 to 211.9)  		 50.0 
 (50.0 to 50.0)  		 50.0 
 (50.0 to 50.0)  		 50.0 
 (50.0 to 50.0) 
Week 104 (N: 15, 9, 4, 7, 1, 6, 2)   1326.1 
 (785.0 to 2240.2)  		 2212.7 
 (406.4 to 12048.4)  		 243.3 
 (28.8 to 2052.4)  		 98.9 
 (30.7 to 318.3)  		 50.0 
 (50.0 to 50.0)  		 50.0 
 (50.0 to 50.0)  		 50.0 
 (50.0 to 50.0) 

No statistical analysis provided for Geometric Mean Titers (GMTs) of Anti-A-beta Immunoglobulin G (IgG) Total Using an Enzyme-linked Immunosorbent Assay (ELISA) at Weeks 2, 4, 6, 8, 10, 14, 16, 24, 28, 30, 40, 50, 54, 56, 66, 78, 91, and 104



3.  Secondary:   GMTs of Anti-A-beta Immunoglobulin M (IgM) Using ELISA at Weeks 2, 4, 6, 8, 10, 14, 16, 24, 28, 30, 40, 50, 54, 56, 66, 78, 91, and 104   [ Time Frame: Baseline, Week 2, 4, 6, 8, 10, 14, 16, 24, 28, 30, 40, 50, 54, 56, 66, 78, 91, and 104 ]

Measure Type Secondary
Measure Title GMTs of Anti-A-beta Immunoglobulin M (IgM) Using ELISA at Weeks 2, 4, 6, 8, 10, 14, 16, 24, 28, 30, 40, 50, 54, 56, 66, 78, 91, and 104
Measure Description The LLOQ was 50 U/mL and when the assay result was below LLOQ (50 U/mL), 25 U/mL was imputed for IgM.
Time Frame Baseline, Week 2, 4, 6, 8, 10, 14, 16, 24, 28, 30, 40, 50, 54, 56, 66, 78, 91, and 104  

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
The immunogenicity population included all randomized participants with documented injection of at least one dose of study drug and at least one immunogenicity data point collected.

Reporting Groups
  Description
ACC 3 μg+QS-21 Participants received 3 μg of ACC-001 and 50 μg of QS-21. Test article was given by intramuscular injection into the deltoid muscle at 0, 1, 3, 6, and 12 months.
ACC 10 μg+QS-21 Participants received 10 μg of ACC-001 and 50 μg of QS-21. Test article was given by intramuscular injection into the deltoid muscle at 0, 1, 3, 6, and 12 months.
ACC 30 μg+QS-21 Participants received 30 μg of ACC-001 and 50 μg of QS-21. Test article was given by intramuscular injection into the deltoid muscle at 0, 1, 3, 6, and 12 months.
ACC 10 μg Participants received 10 μg of ACC-001. Test article was given by intramuscular injection into the deltoid muscle at 0, 1, 3, 6, and 12 months.
ACC 30 μg Participants received 30 μg of ACC-001. Test article was given by intramuscular injection into the deltoid muscle at 0, 1, 3, 6, and 12 months.
QS-21 Alone Participants received 50 μg of QS-21. Test article was given by intramuscular injection into the deltoid muscle at 0, 1, 3, 6, and 12 months.
Phosphate Buffered Saline Participants received Phosphate buffered Saline (PBS). Test article was given by intramuscular injection into the deltoid muscle at 0, 1, 3, 6, and 12 months.

Measured Values
   ACC 3 μg+QS-21   ACC 10 μg+QS-21   ACC 30 μg+QS-21   ACC 10 μg   ACC 30 μg   QS-21 Alone   Phosphate Buffered Saline 
Participants Analyzed 
[Units: Participants]
 		 36   60   40   35   12   44   17 
GMTs of Anti-A-beta Immunoglobulin M (IgM) Using ELISA at Weeks 2, 4, 6, 8, 10, 14, 16, 24, 28, 30, 40, 50, 54, 56, 66, 78, 91, and 104 
[Units: U/mL]
Geometric Mean (95% Confidence Interval) 		             
Baseline (N: 36, 59, 40, 35, 12, 44, 17)   32.3 
 (24.6 to 42.4)  		 38.2 
 (30.8 to 47.2)  		 34.2 
 (27.7 to 42.2)  		 32.9 
 (28.1 to 38.5)  		 40.3 
 (27.1 to 59.9)  		 30.8 
 (26.4 to 36.0)  		 25.0 
 (25.0 to 25.0) 
Week 2 (N: 35, 60, 39, 35, 12, 43, 16)   85.1 
 (54.2 to 133.8)  		 127.7 
 (79.5 to 205.0)  		 254.5 
 (133.6 to 484.9)  		 46.5 
 (32.4 to 66.7)  		 76.9 
 (40.5 to 146.2)  		 31.5 
 (26.6 to 37.3)  		 26.5 
 (23.4 to 29.9) 
Week 4 (N: 35, 57, 38, 31, 12, 43, 16)   82.3 
 (52.8 to 128.4)  		 123.4 
 (75.9 to 200.7)  		 276.6 
 (143.3 to 533.6)  		 48.2 
 (33.2 to 70.2)  		 92.0 
 (46.7 to 181.1)  		 33.2 
 (28.0 to 39.3)  		 27.3 
 (24.0 to 30.9) 
Week 6 (N: 36, 58, 37, 33, 12, 41, 16)   626.5 
 (340.5 to 1152.8)  		 1283.8 
 (742.6 to 2219.4)  		 1736.6 
 (906.4 to 3327.1)  		 72.3 
 (40.8 to 128.2)  		 144.1 
 (55.9 to 371.6)  		 31.1 
 (26.6 to 36.3)  		 25.0 
 (25.0 to 25.0) 
Week 8 (N: 33, 57, 39, 33, 12, 41, 17)   758.9 
 (388.6 to 1482.4)  		 1903.8 
 (1097.7 to 3301.9)  		 2769.5 
 (1407.2 to 5450.9)  		 70.8 
 (40.8 to 123.0)  		 166.4 
 (60.3 to 459.3)  		 31.0 
 (26.1 to 36.8)  		 26.3 
 (23.6 to 29.4) 
Week 10 (N: 34, 59, 40, 33, 12, 43, 17)   595.2 
 (310.0 to 1143.0)  		 1697.7 
 (980.8 to 2938.6)  		 2598.1 
 (1382.6 to 4882.0)  		 69.9 
 (38.3 to 127.6)  		 157.1 
 (56.1 to 440.1)  		 36.3 
 (28.0 to 47.9)  		 27.3 
 (24.0 to 31.1) 
Week 14 (N: 33, 52, 39, 31, 11, 33, 14)   770.2 
 (416.1 to 1425.6)  		 2721.0 
 (1608.3 to 4603.4)  		 5271.3 
 (2904.4 to 9567.3)  		 80.8 
 (40.2 to 162.3)  		 290.7 
 (71.8 to 1177.7)  		 31.0 
 (25.5 to 37.8)  		 25.0 
 (25.0 to 25.0) 
Week 16 (N: 33, 59, 38, 34, 12, 41, 16)   727.3 
 (395.0 to 1339.0)  		 3098.3 
 (1904.1 to 5041.2)  		 5666.4 
 (3264.6 to 9835.3)  		 93.4 
 (47.5 to 183.4)  		 271.8 
 (70.5 to 1047.5)  		 34.5 
 (27.6 to 43.0)  		 25.0 
 (25.0 to 25.0) 
Week 24 (N: 34, 58, 37, 33, 10, 40, 16)   461.3 
 (260.4 to 817.2)  		 1862.5 
 (1137.9 to 3048.3)  		 2672.4 
 (1553.6 to 4597.0)  		 90.8 
 (48.1 to 171.3)  		 296.2 
 (56.3 to 1549.6)  		 30.9 
 (26.1 to 36.7)  		 26.6 
 (23.3 to 30.2) 
Week 28 (N: 31, 51, 33, 29, 8, 36, 16)   669.0 
 (388.0 to 1153.6)  		 1915.3 
 (1256.2 to 2920.0)  		 3593.2 
 (2050.4 to 6296.9)  		 105.5 
 (50.2 to 221.6)  		 590.9 
 (63.4 to 5511.6)  		 31.3 
 (26.1 to 37.5)  		 25.0 
 (25.0 to 25.0) 
Week 30 (N: 33, 56, 36, 32, 10, 38, 16)   717.3 
 (432.6 to 1189.5)  		 2259.4 
 (1524.0 to 3349.6)  		 4147.2 
 (2423.1 to 7098.1)  		 128.4 
 (63.1 to 261.1)  		 343.3 
 (49.9 to 2361.4)  		 37.8 
 (27.7 to 51.6)  		 25.0 
 (25.0 to 25.0) 
Week 40 (N: 32, 54, 33, 33, 9, 37, 15)   559.0 
 (350.7 to 891.0)  		 1351.6 
 (885.3 to 2063.3)  		 1855.9 
 (1074.3 to 3206.1)  		 103.9 
 (54.2 to 199.3)  		 311.9 
 (39.1 to 2491.7)  		 34.2 
 (28.1 to 41.6)  		 25.0 
 (25.0 to 25.0) 
Week 50 (N: 29, 53, 33, 33, 9, 36, 16)   351.3 
 (210.2 to 587.2)  		 1049.6 
 (701.4 to 1570.8)  		 1246.4 
 (707.2 to 2196.7)  		 84.7 
 (45.6 to 157.3)  		 294.6 
 (41.2 to 2104.6)  		 32.2 
 (27.1 to 38.3)  		 25.0 
 (25.0 to 25.0) 
Week 54 (N: 27, 51, 30, 29, 9, 29, 14)   477.7 
 (305.2 to 747.7)  		 1529.1 
 (1045.4 to 2236.7)  		 2479.5 
 (1373.5 to 4476.4)  		 121.1 
 (52.1 to 281.7)  		 436.9 
 (52.1 to 3662.2)  		 36.2 
 (28.4 to 46.3)  		 27.2 
 (22.7 to 32.5) 
Week 56 (N: 31, 52, 34, 32, 9, 34, 15)   598.7 
 (375.1 to 955.5)  		 1696.1 
 (1173.6 to 2451.3)  		 2681.8 
 (1480.7 to 4857.0)  		 109.8 
 (49.4 to 244.1)  		 438.5 
 (51.5 to 3734.3)  		 34.3 
 (27.2 to 43.2)  		 29.5 
 (22.6 to 38.6) 
Week 66 (N: 31, 54, 34, 31, 9, 33, 15)   457.6 
 (282.2 to 742.1)  		 1422.0 
 (980.7 to 2061.9)  		 1637.2 
 (961.9 to 2786.6)  		 114.3 
 (51.6 to 253.1)  		 342.1 
 (41.2 to 2839.9)  		 36.1 
 (26.5 to 49.1)  		 27.8 
 (23.8 to 32.6) 
Week 78 (N: 31, 52, 32, 32, 8, 32, 14)   368.2 
 (238.4 to 568.7)  		 1204.4 
 (815.6 to 1778.6)  		 1217.7 
 (706.1 to 2100.1)  		 107.5 
 (52.2 to 221.4)  		 346.0 
 (31.2 to 3832.0)  		 34.6 
 (27.9 to 43.0)  		 28.9 
 (23.4 to 35.8) 
Week 91 (N: 15, 9, 3, 8, 2, 6, 2)   391.2 
 (205.6 to 744.2)  		 1203.4 
 (399.9 to 3621.9)  		 679.2 
 (28.5 to 16208.4)  		 98.9 
 (18.4 to 530.4)  		 25.0 
 (25.0 to 25.0)  		 28.3 
 (20.5 to 39.1)  		 25.0 
 (25.0 to 25.0) 
Week 104 (N: 15, 9, 4, 7, 1, 6, 2)   299.1 
 (144.2 to 620.8)  		 1561.8 
 (438.0 to 5569.0)  		 620.3 
 (78.8 to 4882.2)  		 176.7 
 (26.1 to 1197.0)  		 25.0 
 (25.0 to 25.0)  		 25.0 
 (25.0 to 25.0)  		 25.0 
 (25.0 to 25.0) 

No statistical analysis provided for GMTs of Anti-A-beta Immunoglobulin M (IgM) Using ELISA at Weeks 2, 4, 6, 8, 10, 14, 16, 24, 28, 30, 40, 50, 54, 56, 66, 78, 91, and 104



4.  Secondary:   Change From Baseline GMTs of Anti-A-beta IgG Subtypes Using ELISA at Visits Where an IgG Total Response is Measurable (at Weeks 2, 4, 6, 8, 10, 14, 16, 24, 28, 30, 40, 50, 54, 56, 66, 78, 91, and 104 if Applicable)   [ Time Frame: Baseline, Week 2, 4, 6, 8, 10, 14, 16, 24, 28, 30, 40, 50, 54, 56, 66, 78, 91, and 104 ]

Measure Type Secondary
Measure Title Change From Baseline GMTs of Anti-A-beta IgG Subtypes Using ELISA at Visits Where an IgG Total Response is Measurable (at Weeks 2, 4, 6, 8, 10, 14, 16, 24, 28, 30, 40, 50, 54, 56, 66, 78, 91, and 104 if Applicable)
Measure Description IgG subtypes were not assessed
Time Frame Baseline, Week 2, 4, 6, 8, 10, 14, 16, 24, 28, 30, 40, 50, 54, 56, 66, 78, 91, and 104  

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
No text entered.

Reporting Groups
  Description
ACC 3 μg+QS-21 Participants received 3 μg of ACC-001 and 50 μg of QS-21. Test article was given by intramuscular injection into the deltoid muscle at 0, 1, 3, 6, and 12 months.
ACC 10 μg+QS-21 Participants received 10 μg of ACC-001 and 50 μg of QS-21. Test article was given by intramuscular injection into the deltoid muscle at 0, 1, 3, 6, and 12 months.
ACC 30 μg+QS-21 Participants received 30 μg of ACC-001 and 50 μg of QS-21. Test article was given by intramuscular injection into the deltoid muscle at 0, 1, 3, 6, and 12 months.
ACC 10 μg Participants received 10 μg of ACC-001. Test article was given by intramuscular injection into the deltoid muscle at 0, 1, 3, 6, and 12 months.
ACC 30 μg Participants received 30 μg of ACC-001. Test article was given by intramuscular injection into the deltoid muscle at 0, 1, 3, 6, and 12 months.
QS-21 Alone Participants received 50 μg of QS-21. Test article was given by intramuscular injection into the deltoid muscle at 0, 1, 3, 6, and 12 months.
Phosphate Buffered Saline Participants received Phosphate buffered Saline (PBS). Test article was given by intramuscular injection into the deltoid muscle at 0, 1, 3, 6, and 12 months.

Measured Values
   ACC 3 μg+QS-21   ACC 10 μg+QS-21   ACC 30 μg+QS-21   ACC 10 μg   ACC 30 μg   QS-21 Alone   Phosphate Buffered Saline 
Participants Analyzed 
[Units: Participants]
 		 0   0   0   0   0   0   0 
Change From Baseline GMTs of Anti-A-beta IgG Subtypes Using ELISA at Visits Where an IgG Total Response is Measurable (at Weeks 2, 4, 6, 8, 10, 14, 16, 24, 28, 30, 40, 50, 54, 56, 66, 78, 91, and 104 if Applicable)                      

No statistical analysis provided for Change From Baseline GMTs of Anti-A-beta IgG Subtypes Using ELISA at Visits Where an IgG Total Response is Measurable (at Weeks 2, 4, 6, 8, 10, 14, 16, 24, 28, 30, 40, 50, 54, 56, 66, 78, 91, and 104 if Applicable)




  Serious Adverse Events
  Show Serious Adverse Events


  Other Adverse Events
  Show Other Adverse Events


  Limitations and Caveats
  Hide Limitations and Caveats

Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
No text entered.


  More Information
  Hide More Information

Certain Agreements:  
Principal Investigators are NOT employed by the organization sponsoring the study.
There IS an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.
The agreement is:
unchecked The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.
unchecked The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.


Results Point of Contact:  
Name/Title: Pfizer ClinicalTrials.gov Call Center
Organization: Pfizer, Inc.
phone: 1-800-718-1021
e-mail: ClinicalTrials.gov_Inquiries@pfizer.com


Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):


Responsible Party: Pfizer
ClinicalTrials.gov Identifier: NCT00498602     History of Changes
Other Study ID Numbers: 3134K1-2201
B2571005 ( Other Identifier: Alias Study Number )
Study First Received: July 9, 2007
Results First Received: April 23, 2014
Last Updated: November 30, 2015